Ou Z L, Li Y X, Ji L D, Ke M J
Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Department of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhonghua Wai Ke Za Zhi. 2020 Feb 1;58(2):99-104. doi: 10.3760/cma.j.issn.0529-5815.2020.02.005.
Pancreatic cancer is malignant and has a poor prognosis.At present, the treatment mode has changed from "Surgery First" to systemic therapy under multi-disciplinary team, but surgical resection is still the only way to cure pancreatic cancer. In systemic treatment of pancreatic cancer, the effect of postoperative adjuvant therapy is significant, and preoperative neoadjuvant therapy has gradually attracted widespread attention. Neoadjuvant therapy can improve the rate of R0 resection in patients with pancreatic cancer.There is a consensus on neoadjuvant therapy for patients who with borderline resectable and locally advanced, but for the patients who with resectable remains controversial.
胰腺癌是恶性肿瘤，预后较差。目前，治疗模式已从“先手术”转变为多学科团队下的全身治疗，但手术切除仍是治愈胰腺癌的唯一方法。在胰腺癌的全身治疗中，术后辅助治疗效果显著，术前新辅助治疗也逐渐受到广泛关注。新辅助治疗可提高胰腺癌患者的R0切除率。对于可切除边缘和局部晚期患者的新辅助治疗已达成共识，但对于可切除患者的新辅助治疗仍存在争议。
